merrimack
Merrimack shuts down development of investigational cancer drug, staff cuts to follow
April 8, 2019Research and Development, Sales and Marketing cacner, merrimack, oncology, pharma
Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …
Merrimack sells off drug for $1 billion and cuts workforce by 80%
January 9, 2017Sales and Marketing Onivyde, ipsen, merrimack
Ipsen has announced the agreement to acquire oncology assets from Merrimack Pharmaceuticals, most notably the pancreatic cancer drug Onivyde, in …
Merrimack’s breast cancer trial stutters to halt
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merrimack Pharmaceuticals, merrimack
Merrimack Pharmaceuticals announced that it had decided to stop a Phase 2 study of MM-302, a HER2 antibody-targeted liposomal doxorubicin, …
Third failure for Sanofi/Merrimack cancer drug
November 27, 2013Research and Development, Sales and Marketing Cancer, Sanofi, merrimack, mm-121
Sanofi and partner Merrimack have posted yet more disappointing results for their investigational cancer medicine MM-121. In the latest study …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
